You are here

  • Home
  • Online First
  • Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study

Article info

Article menu

other Versions

Download PDFPDF
Original research
Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study

Authors

  • Wenbin Shen Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Chuyu Jing Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Wenjuan Tian Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Wei Zhang Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Yulan Ren Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Boer Shan Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Huaying Wang Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Boer Shan, Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China; shanboer{at}hotmail.com; Dr Huaying Wang, Department of Gynecologic Oncology, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China; wanghuaying270{at}163.com
View Full Text

Citation

Shen W, Jing C, Tian W, et al
Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study
International Journal of Gynecologic Cancer Published Online First: 29 September 2023. doi: 10.1136/ijgc-2023-004777

Publication history

  • Received June 30, 2023
  • Accepted September 7, 2023
  • First published September 29, 2023.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.